Announced details
Adenovirus (AdV) infections following hematopoietic stem cell transplantation
Extremely high efficacy demonstrated in a Phase 2 clinical trial, achieving proof of concept (POC) for antiviral activity
First Patient In (FPI) achieved
Clinical trial site. Michael Grimley, the site's medical director, achieved first patient enrollment.
A medical center in Ohio, US. Its Cancer and Blood Diseases Institute includes a Bone Marrow Transplantation and Immune Deficiency division.
Clinical trial registration number NCT07387367
Cincinnati Children's Hospital Medical Center, Ohio, US
No impact on consolidated results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
Press release dated 30 June 2025; Phase 2 clinical trial
| Item | Details |
|---|---|
| Names of Products / Services Covered | IV BCV (injectable brincidofovir) |
| Counterparty | Cincinnati Children's Hospital Medical Center |
| Counterparty overview | A medical center in Ohio, US. Its Cancer and Blood Diseases Institute includes a Bone Marrow Transplantation and Immune Deficiency division. |
| Relationship with the Company | Clinical trial site. Michael Grimley, the site's medical director, achieved first patient enrollment. |
| Applicable area | Adenovirus (AdV) infections following hematopoietic stem cell transplantation |
| Registration number and expiry date | Clinical trial registration number NCT07387367 |
| Location | Cincinnati Children's Hospital Medical Center, Ohio, US |
| Location scale | A total of 80 sites and enrollment of 180 patients planned |
| Quantitative Effects | Extremely high efficacy demonstrated in a Phase 2 clinical trial, achieving proof of concept (POC) for antiviral activity |
| Usage history | First Patient In (FPI) achieved |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending December 2026 |
| Source | Press release dated 30 June 2025; Phase 2 clinical trial |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There are no effective treatments for adenovirus infections following hematopoietic stem cell transplantation, and the mortality rate is high, creating an urgent need for the development of effective treatments.